Department of Health
and Human Services (HHS)
and Human Services (HHS)
August 10, 2020
PAR-18-528 - NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to inform interested applicants of a change to the Key Dates for PAR-18-528 "NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)" (changes show below in bold italics). This Funding Opportunity Announcement has been extended by one additional council round. The dates have been modified to add the following New Application Due Date: February 5, 2021 and Renewal, Resubmission, Revision Due Date: March 5, 2021.
Currently Reads:
Part 1. Overview Information
Key Dates
| Application Due Date(s) |
Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| Scientific Merit Review | Standard dates apply |
| Advisory Council Review | Standard dates apply |
| Earliest Start Date | Standard dates apply |
| Expiration Date | January 8, 2021 |
Modified to Read:
Part 1. Overview Information
Key Dates
| Application Due Date(s) |
Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| Scientific Merit Review | Standard dates apply |
| Advisory Council Review | Standard dates apply |
| Earliest Start Date | Standard dates apply |
| Expiration Date | March 6, 2021 |
All other aspects of this FOA remain unchanged.
Codrin Lungu, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135
Email: [email protected]